HoldsUp

Elizabeth Parrish

Elizabeth Parrish is a researcher in the field of gene therapy. Her published work investigates gene therapy approaches for healthy life extension, including intranasal and injectable methods, as well as the assessment of biosimilar gene therapies.

22 claims checked on air: 2 context 1 contradicted 4 overstated 8 supported 7 unverified

What they said on air - supported

0:10:34supportedhighIs Aging a Disease? Inside the First Human Gene Therapy Expe

In children with progeria, an LMNA gene defect causes excess progerin production which degrades telomeres at chromosome ends.

"So they have a LMNA gene defect. It creates more progerin in the cell and it degrades the telomeres at the ends of the chromosomes." (said at 0:10:34)

The speaker's statement accurately summarizes the core genetic and cellular mechanism of Hutchinson-Gilford progeria syndrome (HGPS). HGPS is caused by a mutation in the LMNA gene that activates an abnormal splice site, leading to the accumulation of a mutant, truncated lamin A protein called progerin. Progerin disrupts nuclear architecture and genome stability, directly leading to accelerated telomere shortening and telomere dysfunction at chromosome ends.

0:15:00supportedlowIs Aging a Disease? Inside the First Human Gene Therapy Expe

Follistatin gene therapy expressed locally produces follistatin protein that enters the bloodstream to block myostatin and lower inflammatory markers.

"There are genes like follistatin that you could put here and here in your arms, and they actually share the protein throughout your blood system. So the protein goes into your blood, it blocks myostatin, and has a myriad of benefits of lowering inflammatory markers and other things." (said at 0:15:00)

Preclinical and early translational studies confirm the mechanism described: intramuscular delivery of follistatin gene constructs (e.g., AAV-FS344) results in muscle production and secretion of follistatin into the systemic circulation (serum), where it acts as a potent antagonist to myostatin. Additionally, animal models of obesity and joint disease demonstrate that AAV-mediated follistatin gene therapy reduces systemic inflammatory cytokines and adipokines. However, evidence regarding systemic anti-inflammatory benefits remains largely confined to animal models.

0:27:44supportedmoderateIs Aging a Disease? Inside the First Human Gene Therapy Expe

Adeno-associated virus (AAV) does not transfect well through the nasal mucosa.

"it's directed intranasal delivery with needles. Um because um AAV doesn't transfect well through the the mucosa." (said at 0:27:44)

Preclinical and in vitro studies on human airway and nasal epithelial tissues demonstrate that adeno-associated virus (AAV) vectors (specifically standard serotypes such as AAV-2) transduce intact apical mucosal surfaces very poorly. The mucosal barrier, absence of accessible apical receptors, and rapid endosomal/proteasomal degradation significantly restrict gene transfer across the intact airway and nasal mucosa compared to basolateral delivery or direct tissue injection.

0:34:20supportedlowIs Aging a Disease? Inside the First Human Gene Therapy Expe

Research demonstrates a feedback loop between mitochondria and telomere length, with telomerase reverse transcriptase repairing mitochondria by reducing oxidative stress.

"When we looked at telomerase reverse transcriptase, we looked at the the research behind it. It actually seems to have a reparative effect on mitochondria in the same cell by reducing oxidative stress. Now that there is a complete feedback loop between mitochondria and longer telomeres and so it it had been shown in research um this feedback loop." (said at 0:34:20)

Research in cell models and animal studies demonstrates that telomerase reverse transcriptase (TERT) localizes to mitochondria, where it protects mitochondrial DNA and reduces mitochondrial reactive oxygen species (ROS) and oxidative stress. Furthermore, literature establishes a functional reciprocal link (mitochondria-telomere axis) where mitochondrial dysfunction and ROS promote telomere erosion, while TERT expression and mitochondrial localization protect mitochondrial function and maintain cellular homeostasis.

0:34:57supportedvery lowIs Aging a Disease? Inside the First Human Gene Therapy Expe

Alpha-Klotho expression is associated with reduced beta-amyloid plaques in the brain.

"Alpha-Klotho was associated with less beta-amyloid plaques." (said at 0:34:57)

Preclinical animal and cellular models demonstrate that increased expression or lentiviral-mediated overexpression of alpha-Klotho in the brain is associated with reduced amyloid-beta (Aβ) burden and enhanced clearance of Aβ plaques, alongside improved cognitive outcomes in Alzheimer's disease mouse models (such as APP/PS1 mice). Because the direct evidence demonstrating reduced plaque deposition following altered Klotho expression comes primarily from animal and in vitro models, human clinical certainty remains very low.

0:35:30supportedmoderateIs Aging a Disease? Inside the First Human Gene Therapy Expe

PGC-1alpha drives mitochondrial biogenesis that converts white adipose tissue to brown adipose tissue.

"So yes, it's it's it's associated with uh mitochondrial biogenesis turning white fat to brown fat with this excessive amount of little mitochondria that that darken the stain." (said at 0:35:30)

Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is well established as a master transcriptional coactivator of mitochondrial biogenesis and thermogenic gene expression. Activation of PGC-1α drives the recruitment of nuclear respiratory factors and mitochondrial transcription factors, increasing mitochondrial density and oxidative capacity. In white adipose tissue, this process promotes the "browning" (or beigeing) of adipocytes, characterized by dense, iron-rich mitochondria that give brown and beige fat tissue its darker color and thermogenic phenotype.

0:41:26supportedhighIs Aging a Disease? Inside the First Human Gene Therapy Expe

Adeno-associated virus (AAV) vector DNA does not integrate into human chromosomes in over 90% of cases, instead forming an episome.

"The the reason that people love adeno-associated virus is it vastly 90 some percent of the cases creates what's called an episome. So it means it doesn't integrate into the human chromosome" (said at 0:41:26)

Recombinant adeno-associated virus (rAAV) vectors engineered for gene therapy lack the Rep protein required for targeted genomic integration, causing the vector DNA to remain predominantly (>90–99%) extrachromosomal as circular or concatemeric episomes. While chromosomal integration can still occur at very low frequencies (often estimated at under 1% to a few percent of transduction events), the vast majority of rAAV genomes persist episomally in the nucleus.

0:57:00supportedhighIs Aging a Disease? Inside the First Human Gene Therapy Expe

Scientific consensus recognizes twelve hallmarks of biological aging.

"there's 12 agreed-upon hallmarks of aging." (said at 0:57:00)

The widely recognized scientific framework for aging biology, updated by López-Otín and colleagues in Cell (2023), defines twelve hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis. This expanded upon the original nine hallmarks established in 2013.

Fact-checked episodes

Publications